This symposium featured an international line-up of speakers presenting on the discovery and clinical development of novel therapeutic agents. The program included the Society of Medicines Research (SMR) Award Lecture, given by Dr. Betty Chang from Pharmacyclics on the discovery and development of the marketed drug ibrutinib, as well as talks, several representing first U.K. disclosures, on Toll-like receptor 7 (TLR7) agonists, Na v 1.

No abstract

No abstract

No abstract

Collingwood and Andrew Ratcliffe, focused on kinase inhibitors from early research to clinic. Topics included kinase inhibitor design, translating kinase selectivity profiles into early safety guidance, and the discovery and early development of kinase inhibitors in the therapeutic areas of inflammation, pulmonary arterial hypertension and oncology.